{{item.CompanyName | formatName}}{{item.CurrentPrice.Amount | currency: ""}} : {{item.Change.Amount | number:2 }} ({{item.PercentChange.Value | percentChange | customCurrency: "" | trimValue}}%)

Editor's Choice

5 FREE Investing Reports That You Can Download Right Now!

Why Santander, RSA Insurance And N Brown Group Are Irresistible Dividend Stars

Royston Wild explains why income chasers should fill up on these three stocks.

Premium Research: Is Boohoo.com The Next ASOS?

Or has the growth prospects of these two UK fashion companies been overstated?

3 Reasons Why I’d Still Buy Royal Dutch Shell And BG Group

Roland Head explains why investing in Shell and BG today could prove profitable.

Sainsbury’s Gives Up On Selling Food. Didn’t Tesco Try This?

Can SBRY succeed where TSCO failed? Harvey Jones has his doubts.

9.2 Billion Reasons To Buy Rolls-Royce, Cobham, GKN, easyJet & International Consolidated Airlines

Royston Wild explains why these five stocks are set to head higher.

Should You Sell Petrofac, Shire And Standard Chartered?

Do more problems lie ahead for PFC, Shire and STAN?

3 Stocks Offering Terrible Bang For Your Buck

Royston Wild explains why Royal Bank of Scotland, Antofagasta and Soco International are exceptionally poor value right now.

How High (Or Low) Can The FTSE 100 Realistically Go This Year?

Will we see major gains or huge losses for the FTSE 100 during the remainder of the year?

Why Is Neil Woodford So Bullish On British American Tobacco?

VIDEO: One Fool takes a closer look at BATS.

Profit From The Biotech Boom With Vectura, Hikma And Indivior

VEC, HIK and INDV are three top plays on the biotech boom.

Your browser (Internet Explorer 8 or older) is out of date. It has known security flaws and may not display all features of this and other websites. We recommend updating to Google Chrome.